Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WR 279,396 in Cutaneous Leishmaniasis
NCT01790659Phase 3Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- May 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of WR 279,396 in cutaneous leishmaniasis (CL), sponsored by U.S. Army Medical Research and Development Command. Started May 2013; status: completed.
02
Drugs
WR 279,396
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT01790659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01790659.